Summary:
A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients with Difficult-to-treat/Resistant Hypertension.
Qualified Participants Must:
• Be 18 years and older
• Diagnosed with Hypertension, currently treated with 2 medications
• Willing and able to sign consent and comply with study procedures
Qualified Participants May Receive:
Health Checks, Assessments & Physical Examination in relation to study no cost to you. Access to study drug while in study and compensation for qualifying participants.